Although this study suggests that TGFβ1 inhibition could be a tool to prevent or treat EPS, direct and chronic inhibition of systemic TGFβ1 activity is probably not desirable in humans given the important role of TGFβ1 in immune regulation and tumor suppression [25]–[31]. This evidence concerns the gene TGFB1 and neoplasm.